262 related articles for article (PubMed ID: 34054800)
41. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
[TBL] [Abstract][Full Text] [Related]
42. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
[TBL] [Abstract][Full Text] [Related]
43. Provider factors associated with disparities in human papillomavirus vaccination among low-income 9- to 17-year-old girls.
Vadaparampil ST; Staras SA; Malo TL; Eddleton KZ; Christie J; Rodriguez M; Giuliano AR; Shenkman EA
Cancer; 2013 Feb; 119(3):621-8. PubMed ID: 23341308
[TBL] [Abstract][Full Text] [Related]
44. The Vaccine and Cervical Cancer Screen project 2 (VACCS 2): Linking cervical cancer screening to a two-dose HPV vaccination schedule in the South-West District of Tshwane, Gauteng, South Africa.
Snyman LC; Dreyer G; Visser C; Botha MH; van der Merwe FH
S Afr Med J; 2015 Mar; 105(3):191-4. PubMed ID: 26294825
[TBL] [Abstract][Full Text] [Related]
45. A Retrospective Cohort Study of Young Women Spontaneously Choosing to Be Vaccinated against HPV: Outcomes from Their First Cervical Cancer Screening Test.
Del Mistro A; Battagello J; Weis L; Bressan V; Selle V; Ramigni M; Dal Zotto A; Maggiolo A; Gori S; Frayle H; Zappa M; Zorzi M; The Consensus Study Veneto Working Group
Viruses; 2021 Mar; 13(3):. PubMed ID: 33809436
[TBL] [Abstract][Full Text] [Related]
46. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
; Romanowski B; de Borba PC; Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; Aoki F; Ramjattan B; Shier RM; Somani R; Barbier S; Blatter MM; Chambers C; Ferris D; Gall SA; Guerra FA; Harper DM; Hedrick JA; Henry DC; Korn AP; Kroll R; Moscicki AB; Rosenfeld WD; Sullivan BJ; Thoming CS; Tyring SK; Wheeler CM; Dubin G; Schuind A; Zahaf T; Greenacre M; Sgriobhadair A
Lancet; 2009 Dec; 374(9706):1975-85. PubMed ID: 19962185
[TBL] [Abstract][Full Text] [Related]
47. Associations between HPV vaccination among women and their 11-14-year-old children.
Kornides M; Head KJ; Feemster K; Zimet GD; Panozzo CA
Hum Vaccin Immunother; 2019; 15(7-8):1824-1830. PubMed ID: 31295048
[TBL] [Abstract][Full Text] [Related]
48. Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact.
Gilca V; Salmerón-Castro J; Sauvageau C; Ogilvie G; Landry M; Naus M; Lazcano-Ponce E
Vaccine; 2018 Aug; 36(32 Pt A):4800-4805. PubMed ID: 29887322
[TBL] [Abstract][Full Text] [Related]
49. The GARDASIL vaccine can prevent cervical carcinoma caused by human papilloma virus (HPV) (results from our participation and from the study carried out in Greece).
Ansstasiou-Fotaki P; Deligeoroglou E; Kreatsas G
Akush Ginekol (Sofiia); 2007; 46(3):17-20. PubMed ID: 18018777
[TBL] [Abstract][Full Text] [Related]
50. Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study.
Woestenberg PJ; Bogaards JA; King AJ; Leussink S; van der Sande MA; Hoebe CJ; van Benthem BH;
Int J Cancer; 2019 Jun; 144(11):2718-2727. PubMed ID: 30426502
[TBL] [Abstract][Full Text] [Related]
51. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
Arbyn M; Dillner J
J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
[TBL] [Abstract][Full Text] [Related]
52. [Recommendations for the definition of a policy on vaccination against papillomavirus in Mexico. Strategic Advisory Group of Experts of the World Health Organization].
Lazcano-Ponce E; Salmerón-Castro J; García-Carrancá A; Aranda-Flores C; Madrid-Marina V; Gómez-Altamirano CM; Martínez-Montañez OG
Salud Publica Mex; 2009; 51(4):336-41. PubMed ID: 19668929
[No Abstract] [Full Text] [Related]
53. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
[TBL] [Abstract][Full Text] [Related]
54. Human Papillomavirus Vaccination After COVID-19.
Toh ZQ; Russell FM; Garland SM; Mulholland EK; Patton G; Licciardi PV
JNCI Cancer Spectr; 2021 Apr; 5(2):pkab011. PubMed ID: 33748668
[TBL] [Abstract][Full Text] [Related]
55. No Vacillation on HPV Vaccination.
Sipp D; Frazer IH; Rasko JEJ
Cell; 2018 Mar; 172(6):1163-1167. PubMed ID: 29522737
[TBL] [Abstract][Full Text] [Related]
56. The effects of a brief educational intervention on human papillomavirus knowledge and intention to initiate HPV vaccination in 18-26 year old young adults.
Kester LM; Shedd-Steele RB; Dotson-Roberts CA; Smith J; Zimet GD
Gynecol Oncol; 2014 Mar; 132 Suppl 1():S9-12. PubMed ID: 24384459
[TBL] [Abstract][Full Text] [Related]
57. A Qualitative Study of Parental Knowledge and Perceptions of Human Papillomavirus and Cervical Cancer Prevention in Rural Central Java, Indonesia: Understanding Community Readiness for Prevention Interventions.
Spagnoletti BRM; Bennett LR; Wahdi AE; Wilopo SA; Keenan CA
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2429-2434. PubMed ID: 31450917
[TBL] [Abstract][Full Text] [Related]
58. Facilitators and barriers of human papillomavirus vaccine uptake in young females 18-26 years old in Singapore: A qualitative study.
Lim ASE; Lim RBT
Vaccine; 2019 Sep; 37(41):6030-6038. PubMed ID: 31473002
[TBL] [Abstract][Full Text] [Related]
59. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
60. Human papillomavirus vaccination and the primary prevention of cancer: implications for survivors of childhood cancer.
Klosky JL; Foster RH; Hodges J; Peasant C; Gamble H; McDermott MJ; Rao P
Stud Health Technol Inform; 2012; 172():33-42. PubMed ID: 22910499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
